Pharmacodynamics and Tolerance of Nicotinamide Mononucleotide (NMN, 400mg/Day) in Healthy Adults

Pharmacodynamics and Tolerance Study of Nicotinamide Mononucleotide (NMN) Supplementation at 400 mg/Day

The purpose of this study is to evaluate the physiological and/or biological actions of nicotinamide mononucleotide (NMN-C) in healthy adults receiving a repeated-dose over the course of 28 days by studying the tolerance and pharmacodynamics of this product.

Inclusion Criteria:

Healthy volunteers should be

• Men between the ages of 30 and 60 years old
• With a BMI between 23 and 30 kg/m2
• With a weight > or = 70kg
• Giving their free informed consent to the study

Exclusion Criteria:

May not be included in the study Volunteers with

• a history of allergy to vitamin B3 (niacin or nicotinamide)
• immunocompromised or suffering from a serious or progressive disease (cardiac, pulmonary, hepatic, renal, hematologic, neoplastic or infectious)
• with abnormal results on the screening bioassay (CBC, Transaminases (AST, ALT, GGT), Bilirubin, Creatinine, CPK, Ionogram, Blood glucose, Hba1c, Lipid profile)
• having donated blood in the month preceding inclusion,
• having consumed more than 2 glasses of alcohol per day,
• being under medication or taking food supplements,
• having reached the maximum compensation threshold for research involving the human being as provided for by the regulations or having participated in another biomedical research project that required blood samples in the previous month,
• involved in another clinical trial or being in the exclusion period of a previous clinical trial.